FDA-approved Sexual & reproductive

Goserelin

Goserelin is a GnRH agonist. It is filed in this library under sexual & reproductive, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.

Regulatory status

Goserelin has an FDA-approved product on the U.S. market, marketed as Zoladex under application NDA019726.

The current label is held by TerSera Therapeutics LLC.

From the FDA label

What Goserelin is approved to treat

is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate Palliative treatment of advanced carcinoma of the prostate The management of endometriosis Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women 1.1 Stage B2-C Prostatic Carcinoma ZOLADEX is indicated for use in combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment with ZOLADEX and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see Dosage and Administration and Clinical Studies ].Quoted from the FDA-approved prescribing information

The evidence

What has actually been published

One source on Goserelin, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.

Nearby

Other peptides acting on sexual & reproductive

Markers on this pathway

What is measured when the pituitary-gonadal axis is assessed

Goserelin's FDA-approved label indicates it for a condition managed by suppressing or controlling gonadotropin release. These are the markers clinicians use when assessing the pituitary-gonadal axis. They are listed here so you can read about them, not as a statement that Goserelin changes any of them.

Not sure what applies to you?

A 60-second questionnaire, reviewed by a U.S.-licensed physician.

Find my protocol

Educational reference only. This page explains what has been published about Goserelin. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.

Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.

All 150 peptides